Perrigo Co. PLC sees its Rx generic business as part of its core, but a hedge fund with 4.6% stake in the OTC private label giant recommends divesting the business along with Perrigo's Tysabri royalty license to help turn around the firm's plummeting share value.
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor
Starboard Value states says Perrigo "severely mismanaged" its entry into branded consumer health through the acquisition of a German firm and showed "misguided confidence" in encouraging shareholders to reject Mylan's tender.
More from Deals
• By
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
More from Business
• By
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
• By
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.